Are 96-week data enough for doravirine to DRIVE FORWARD?

Affiliations

¹ Technical University of Munich, School of Medicine, Munich, Germany.
² Royal Free London NHS Foundation Trust, London, UK. Electronic address: t.barber@nhs.net.

Comment

Christoph D Spinner et al. Lancet HIV. 2020 Jan.

. 2020 Jan;7(1):e2-e3.

doi: 10.1016/S2352-3018(19)30370-4. Epub 2019 Nov 15.

¹ Technical University of Munich, School of Medicine, Munich, Germany.
² Royal Free London NHS Foundation Trust, London, UK. Electronic address: t.barber@nhs.net.

No abstract available

Comment on

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.